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ABSTRACT
Introduction: To assess the real-life clinical
benefits and cost implications of switching from
another basal insulin to insulin degludec
(degludec) in patients with type 1 diabetes
(T1D) on basal–bolus regimens with recurrent
hypoglycemia and/or hypoglycemia
unawareness.
Methods: Patients with T1D who were
aged C 18 years, were on a basal–bolus regimen,
and had switched to degludec plus bolus insulin
for at least 6 months were included. Patients
had to have switched to degludec as a result of
recurrent hypoglycemia and/or hypoglycemia
unawareness.
Results: Six months of follow-up data were
available for 42 patients. At 6 months, there was
a significant reduction in median (interquartile
range) HbA1c, from 8.6 (8.0–9.3)% [70 (64–78)
mmol/mol] to 8.4 (7.9–8.9)% [68 (63–74)
mmol/mol]; p\0.05. Median daily basal insu-
lin dose reduced significantly from 30.0
(14.7–45.0) to 25.5 (14.0–30.2) units;
p\0.0001. Data from hospital records showed
reductions in the frequency of episodes of sev-
ere hypoglycemia from eight in the 6 months
preceding degludec initiation to two in the
6 months following initiation. In the same
period, diabetic ketoacidosis (DKA) episodes
reduced from two before degludec initiation to
no episodes after initiation. No patients repor-
ted worsening treatment satisfaction after
switching to degludec. Considering the reduc-
tions in the basal dose required and the fre-
quency of hypoglycemia episodes, we estimate
that switching such patients to degludec from
other basal insulins could provide significant
savings in direct healthcare costs.
Conclusion: In patients with T1D, switching to
degludec was associated with an improvement
in HbA1c and reductions in basal insulin dose,
Enhanced content To view enhanced content for this
article go to https://doi.org/10.6084/m9.figshare.
5933110.
M. A. Karamat (&)  S. Bellary  A. A. Tahrani
Department of Diabetes and Endocrinology,
Diabetes Centre, Heartlands Hospital, Birmingham,
UK
e-mail:
muhammad.karamat@heartofengland.nhs.uk
M. A. Karamat  A. A. Tahrani
Institute of Metabolism and Systems, School of
Clinical and Experimental Medicine, University of
Birmingham, Birmingham, UK
M. A. Karamat  A. A. Tahrani
Centre of Endocrinology, Diabetes and Metabolism,
Birmingham Health Partners, Birmingham, UK
S. Dar
Department of Diabetes and Endocrinology, Queen
Elizabeth Hospital, Birmingham, UK
S. Bellary
School of Life and Health Sciences, Aston
University, Aston Triangle, Birmingham, UK
Diabetes Ther (2018) 9:839–849
https://doi.org/10.1007/s13300-018-0400-x
severe hypoglycemia, and DKA. When used in
appropriate patients, degludec could lead to
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INTRODUCTION
Hypoglycemia in patients with type 1 diabetes
(T1D) represents a considerable economic bur-
den to the UK National Health Service (NHS).
Data from the West Midlands Ambulance Ser-
vice show that between January 1, 2013 and
December 31, 2014 in the West Midlands region
of the UK (covering a population of 5.6 million
[1]), there were 3813 ambulance call-outs rela-
ted to hypoglycemia, costing the NHS over
£900,000 [2]. During the same period, hospital
admissions attributed to a primary diagnosis of
hypoglycemia were estimated to cost £464,760
[3]. Hypoglycemia can have considerable nega-
tive effects on patient quality-of-life (QoL), with
an increased frequency and severity of hypo-
glycemic episodes associated with greater
reductions in QoL [4]. Severe hypoglycemia is
associated with an increased risk of falls, frac-
tures, cardiovascular disease, major adverse
cardiovascular events, major microvascular
events, dementia (in older patients) and death
[5–8].
Insulin degludec (degludec) is a long-acting
basal insulin with a duration of action extend-
ing to over 40 h in most patients at therapeutic
doses [9]. It has a flat pharmacodynamic profile
at steady state, with less injection-to-injection
variability in glucose-lowering activity than
insulin glargine 100 units/mL (glargine U100)
[9, 10]. Randomized controlled trials (RCTs) in
patients with T1D and type 2 diabetes (T2D)
have shown that, compared with glargine U100,
degludec leads to a reduced risk of hypo-
glycemia, particularly nocturnal hypoglycemia,
at equivalent levels of glycemic control across a
broad spectrum of patients [11–13]. Degludec
has also been associated with improved QoL
scores in phase 3 clinical trials compared with
glargine U100 in T1D and T2D [14]. RCTs are
the gold standard for developing evidence on
the safety and efficacy of new treatment
options, but their well-known limitations, such
as their strictly defined inclusion and exclusion
criteria, restrict the generalizability of their
results to the more heterogeneous populations
of patients encountered in clinical practice [15].
Real-world studies can provide a valuable addi-
tional source of evidence that complements
clinical trial data and helps to bridge the
knowledge gap between RCTs and real-world
practice. To date, a small number of non-inter-
ventional studies have evaluated the clinical
effectiveness and safety of switching to deglu-
dec from other basal insulins in real-world
clinical practice [16–18]. These studies report
improved glycemic control and a reduced risk of
hypoglycemia after switching to degludec from
regimens involving other basal insulins in
patients with T1D or T2D [16–18].
A recent short-term health economic analysis
based on data from the phase 3a registration trials
andmodeling based on the UKNHS setting found
degludec to be dominant (more effective at a
lower cost) over glargine U100 in patients with
T1D or patients with T2D on basal-only therapy,
and cost-effective for T2D and a basal–bolus regi-
men [19]. Scenario analyses versus two recently
marketed basal insulin analogs indicated that
degludec would likely be cost-effective versus
glargine 300 units/mL and biosimilar glargine
across diabetes types and treatment regimens [19].
However, the trials included in this analysis
excluded patients with a history of recurrent
hypoglycemia and those at a high risk of hypo-
glycemia, such as patients with hypoglycemic
unawareness, where degludec might be particu-
larly beneficial in a clinical setting.
This prospective, real-world study was
therefore undertaken to investigate the effects
of switching basal insulin to degludec in T1D
patients with problematic hypoglycemia,
including hypoglycemia unawareness. Study
endpoints included changes in glycemic con-
trol, basal insulin dose, rates of hypoglycemia,
and changes in hypoglycemia unawareness
status and QoL. An exploratory analysis of the
cost-effectiveness of switching to degludec was
also carried out.
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METHODS
This was a prospective, quality-improvement
project in patients with T1D attending the
outpatient clinics at the Heart of England NHS
Foundation Trust (the Trust) (see Fig. 1 for pro-
ject design). Data were extracted retrospectively
to compare clinical outcomes and QoL in
patients with T1D and problematic hypo-
glycemia who were switched to degludec from
regimens that included other basal insulins, as
part of routine clinical practice. The audit was
registered and the data were collected as part of
routine clinical care and subject to the Trust’s
usual governance regulations. Patients were
included in the study if they:
• Had T1D and attended the outpatient clinics
at the Trust;
• Were aged C 18 years;
• Were on an insulin regimen comprising
either a basal–bolus regimen or biphasic
insulin, and
• Had one or more of the following:
• Recurrent severe or nocturnal
hypoglycemia
• Documented hypoglycemia unawareness,
as identified from the patients’ blood
glucose (BG) diaries and/or data from a
continuous glucose monitor.
All eligible patients were reviewed by a
physician and offered the option of switching
their basal insulin or biphasic insulin after
excluding all other reasonable options to
improve control, such as changing the timing of
the basal insulin injections and splitting the
dose between more than one daily injection. All
patients had also received structured diabetes
education, such as the Bournemouth Type 1
Diabetes Education Programme, well before
commencing treatment with degludec, as part
of routine clinical practice for patients with
T1D. No education programs were initiated as
part of the treatment switch. Eligible patients
were then switched to degludec and any previ-
ous basal/biphasic insulins were discontinued.
Patients were advised to take degludec admin-
istered daily in the morning, initiated with a
20% dose reduction from the previous basal
insulin dose. Doses were subsequently titrated
as required. Bolus insulin was administered at
mealtimes. All patients were followed up for a
period of 6 months.
Demographic details, HbA1c levels, previous
basal insulin dose, previous episodes of diabetic
ketoacidosis (DKA), and episodes of hypo-
glycemia [defined as BG B 70.3 mg/dL
(3.9 mmol/L)] were recorded for all patients for
6 months before and for 6 months after the
initiation of degludec. Episodes of hypo-
glycemia were recorded via home BG monitor-
ing or continuous glucose monitoring systems
(for a subset of patients) and recorded in
patients’ BG diaries. Data on the number of
episodes of DKA and ambulance call-outs for
6 months before and 6 months after starting
degludec were obtained from hospital records.
At degludec initiation and at the 6-month
follow-up, patients completed a diabetes ques-
tionnaire based on the Clarke Hypoglycemia
Questionnaire as part of routine clinical care for
Fig. 1 Quality improvement project design. Asterisk indi-
cates a total of 45 patients were included in the project,
three of whom discontinued degludec and initiated
continuous subcutaneous insulin infusion at the physi-
cian’s discretion; Dagger symbol indicates excluding regi-
mens with degludec
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patients with T1D and problematic hypo-
glycemia [20]. This is a self-reported measure of
the number of episodes of hypoglycemia and of
the extent that patients experienced hypo-
glycemia unawareness. At the 6-month follow-
up, patients completed a satisfaction question-
naire, which included questions about fear of
hypoglycemia, confidence in efficacy of treat-
ment, predictability of BG readings, concerns
over diabetes, treatment satisfaction, and whe-
ther the patient was happy to continue
treatment.
Statistical Analysis
Paired-sample t tests were carried out to com-
pare changes in HbA1c at baseline and at the
6-month follow-up. A related-sample Wilcoxon
signed-rank test was used to compare basal
doses at baseline (before the switch to degludec)
and at the 6-month follow-up. Missing data
were dealt with using list-wise deletion.
An exploratory cost-effectiveness analysis
was performed to provide an illustrative exam-
ple of the costs associated with switching to
degludec from other basal insulins in patients
with T1D and problematic hypoglycemia as part
of routine clinical practice. For the purposes of
this cost analysis, severe hypoglycemia was
defined as an episode requiring an ambulance
call-out and/or hospital admission. Data from
hospital records and the West Midlands
Ambulance Service were used to estimate the
change in the number of severe hypoglycemic
events experienced in the 6-month period
before and after switching to degludec. These
data and basal insulin costs (taken as glargine
U100 for the pre-switch arm) based on UK list
prices [21] were used to estimate any cost sav-
ings [in pounds sterling (GBP), based on 2016
costs and values] caused by patients switching
to degludec (due to reductions in the number of
severe hypoglycemic events and the basal
insulin dose); see Fig. 2 for an overview of the
cost-effectiveness model. The average annual
change in cost per patient attributable to the
reduced incidence of severe hypoglycemia upon
switching to degludec was offset against the
difference in the average annual insulin
treatment costs, accounting for any change in
dose requirement.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Baseline Characteristics
A total of 45 patients were initially approached
to be included in the study, but three patients
discontinued degludec and were switched to
continuous subcutaneous insulin infusion, at
their physician’s discretion. Therefore, 42
patients met the inclusion criteria and provided
data. Demographic and clinical characteristics
of the cohort are shown in Table 1. Degludec
dose values at initiation were missing for four
patients; degludec dose values at follow-up were
missing for eight patients; HbA1c values at fol-
low-up were missing for four patients. Some of
this missing information was the result of fail-
ure to attend the 6-month follow-up clinic
appointments. At the beginning of the study,
the basal insulins given to the patients were
glargine U100 (Lantus, Sanofi–Aventis US LLC,
Bridgewater, NJ, USA; n = 23); insulin detemir
(Levemir, Novo Nordisk A/S; n = 17); biphasic
insulin lispro (Humalog Mix25, Eli Lilly
Nederland B.V., Utrecht, The Netherlands;
n = 1; Novomix30, n = 1); or Insulatard (Novo
Nordisk A/S; n = 1). At degludec initiation, 31
(74%) patients were experiencing disabling and/
or recurrent nocturnal hypoglycemia and 11
(26%) had hypoglycemia unawareness.
Endpoints
At the 6-month follow-up, there was a signifi-
cant reduction in mean (standard deviation)
HbA1c from 8.7 (1.3) % [72 (14) mmol/mol] to
8.4 (1.1) % [68 (12) mol/mol]; p\0.05. Median
(interquartile range) daily basal insulin dose
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reduced significantly from 30.0 (14.7–45.0 units
to 25.5 (14.0–30.2) units; p\0.0001. For the 39
patients previously on another basal–bolus reg-
imen, data on insulin (carbohydrate ratios,
type, and average dose of bolus) were available
for 31 of them. Of these, only one patient’s
insulin:carbohydrate ratio had increased at fol-
low-up; eight reduced and 22 did not change.
Two patients experienced an episode of DKA
in the 6 months before degludec initiation;
there were no DKA events in the 6 months after
degludec initiation. There were eight episodes
of severe hypoglycemia in the 6 months before
degludec initiation, and two episodes in the
6-month follow-up period.
All patients completed the Clarke Hypo-
glycemia Questionnaire (Table 2) and the
Patient Satisfaction Questionnaire (Table 3).
The percentage of patients who reported expe-
riencing more than two episodes of moderate
hypoglycemia in the past 6 months decreased
from 31% before to 8% after degludec initia-
tion. No patients reported worsening treatment
satisfaction after switching to degludec.
Fig. 2 Overview of the cost-effectiveness model for switch-
ing to degludec from other basal insulins. Previous regimens
included basal–bolus therapy and biphasic insulin. Dosage
was the mean basal insulin dose. Severe hypoglycemia was
deﬁned as an event requiring an ambulance call-out for the
purposes of this analysis. Asterisk indicates that two
patients who received biphasic insulin before initiating
degludec were included; dagger symbol indicates that the
costs were calculated for glargine 100 units/mL; double
dagger symbol indicates the direct cost of an episode
(excluding ambulance call-out and/or hospital admission)
for Birmingham and the surrounding area
Table 1 Baseline characteristics of the patients enrolled in
the study
Characteristic Baseline value
Number of patients 42
Mean age, years (± SD)
Range, years
50.4 (± 14.0)
22–80
Female/male (%) 64.3/35.7
Duration of diabetes, years (± SD)
Range (years)
26.1 (± 12.2)
4–48
HbA1c, % (± SD) [mmol/mol]
Range, % [mmol/mol]
8.7 (± 1.3) [72 (14)]
5.9–12.2 [41–110]
Mean basal insulin dose
pre-switch (U)
Range (U)
36.8 (29.4)
6–150
Mean degludec starting dose (U)
Range (U)
29.2 (23.7)
4–120
HbA1c glycated hemoglobin, SD standard deviation,
U units
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Cost-Effectiveness
Before switching to degludec, the majority of
patients (n = 22) were taking glargine U100,
which is therefore taken as an illustrative
example with which to assess the potential cost
impact of switching to degludec. After taking
into account the average daily basal insulin
dose for patients immediately before switching
to degludec and the local product costs at the
time of study, the average annual costs per
patient for glargine U100 and degludec in
patients with T1D with problematic hypo-
glycemia were estimated to be £376.10 and
£336.51, respectively [22].
The estimated direct cost (excluding ambu-
lance call-out and/or hospital admission) of an
episode of severe hypoglycemia in patients with
T1D in the greater Birmingham and surround-
ing area was taken as £189.20 [1]. Based on
these data, it was estimated that the annual
total direct cost of severe hypoglycemia per
patient was £72.08 and £19.92 before and after
switching to degludec. Taking into account the
reduced basal dose and reduced number of
severe hypoglycemic events, it is conservatively
estimated that for this cohort of patients,
switching to degludec saved at least £91.75 per
patient per year (based on the 2016 treatment
costs for degludec and glargine U100).
DISCUSSION
In patients with T1D and problematic hypo-
glycemia, switching basal insulin to degludec
resulted in a significant reduction in both HbA1c
and total basal insulin dose without a corre-
sponding increase in bolus dose. There were
also reductions in the number of episodes of
DKA and moderate and severe hypoglycemia.
Insulin therapy is required to control BG
levels in patients with T1D, but is associated
with hypoglycemia, the major barrier to insulin
titration and optimal glycemic control [23].
Advanced age, longer diabetes duration and
lower HbA1c have all been associated with an
increased risk of hypoglycemia in patients with
diabetes [24, 25]. The phase 3b SWITCH 1 trial
Table 2 Results from the Clarke Hypoglycemia Questionnaire
Question Number of patients (%)
6 months before degludec initiation 6 months after degludec initiation
How often patients experienced moderate hypoglycemia
Never 13 (31) 33 (77)
Once or twice 16 (38) 6 (15)
More than twice 13 (31) 3 (8)
Lowest blood glucose range in which symptoms were experienced
59.5–68.5 mg/dL (3.3–3.8 mmol/L) 17 (41) 25 (59)
50.5–57.7 mg/dL (2.8–3.2 mmol/L) 11 (25) 11 (25)
\50.5 mg/dL (\ 2.8 mmol/L) 14 (34) 6 (16)
Extent that hypoglycemia could be predicted by symptoms
Rarely 20 (46) 3 (8)
Sometimes 6 (15) 6 (15)
Often 3 (8) 10 (23)
Always 13 (31) 23 (54)
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(NCT02034513) enrolled patients with T1D
who had at least one hypoglycemia risk factor
(e.g. a T1D duration of more than 15 years), and
showed significantly lower rates of hypo-
glycemia with degludec compared with glargine
U100 at equivalent HbA1c, with the benefit
being relatively greater in magnitude than in
the earlier phase 3a studies [12, 26]. We there-
fore anticipated that degludec would have
greater benefits in patients particularly prone to
hypoglycemia, and our results show that not
only is the risk of hypoglycemia reduced in such
patients, but there is also an improvement in
glycemic control without an increase in insulin
dose for the majority of patients.
Frequent episodes of hypoglycemia can lead
to hypoglycemia unawareness, which is associ-
ated with altered counter-regulation and is
more common in older patients with a long
duration of diabetes [27]. In this prospective
quality-improvement project, patients reported
an improvement in recognizing symptoms of
hypoglycemia, with more patients experiencing
symptoms at higher BG levels [59.5–68.5 mg/dL
(3.3–3.8 mmol/L)] after switching to degludec
versus\59.5 mg/dL (\3.3 mmol/L) before
switching. This is likely a result of the reduced
incidence of hypoglycemia with degludec, since
recurrent episodes can lead to impaired glucose
counter-regulation and reduced hypoglycemia
awareness [28]. In turn, impaired hypoglycemia
awareness increases the risk of severe episodes
between three- and fivefold [29, 30]. However,
the normal hierarchy of hypoglycemia symp-
tom recognition before cognitive dysfunction
can be restored in patients if hypoglycemia is
avoided [31].
In addition, we report that degludec treat-
ment was associated with a reduced fear of
hypoglycemia. Long-term effects of hypo-
glycemia can include behavioral changes as well
as a significant anxiety or fear of future events
[4]. Fear of hypoglycemia can adversely affect
diabetes management and clinical outcomes
through reduced adherence to medications or a
reluctance of physicians to titrate insulin more
aggressively [32, 33]. It is common for patients
to maintain elevated BG levels because of a fear
of hypoglycemia [34]; thus, reducing this fear
may have contributed to the improved HbA1c
Table 3 Results from the Patient Satisfaction
Questionnaire
Question Number of patients
(percentage) 6 months
after degludec initiation
Fear of hypoglycemia
Worse 0 (0)
No change 9 (21)
Improved 26 (62)
Much improved 7 (17)
Conﬁdence in efﬁcacy of treatment
Worse 0 (0)
No change 3 (7)
Improved 38 (91)
Much improved 1 (2)
Predictability of blood glucose readings
Worse 0 (0)
No change 6 (14)
Improved 34 (81)
Much improved 2 (5)
Concerns about diabetes
Worse 0 (0)
No change 7 (17)
Improved 30 (71)
Much improved 5 (12)
Treatment satisfaction
Worse 0 (0)
No change 3 (7)
Improved 32 (76)
Much improved 7 (17)
Would like to continue treatment
Yes 41 (98)
No 1 (2)
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levels observed in this study. Furthermore, both
hypoglycemia unawareness and recurrent sev-
ere hypoglycemia can lead to a fear of hypo-
glycemia, which in turn can reduce adherence
to therapeutic decisions [35]. Thus, the clinical
benefits of switching to degludec may also
contribute to improved well-being and treat-
ment adherence. Degludec was also associated
with an improvement in diabetes-related QoL.
Six months after starting degludec treatment,
41 of the 42 patients in this study said they
would prefer to continue this treatment. Over-
all, degludec was found to be well tolerated, BG
values were seen as more predictable compared
with other basal insulins, confidence in the
treatment was high, and diabetes-related con-
cerns were reduced.
Newer, long-acting insulin analogs offer the
advantage of flexibility, once-daily dosing, and
less risk of hypoglycemia compared with older,
cheaper human insulin analogues such as neu-
tral protamine Hagedorn insulin [36, 37]. Basal
insulin unit costs vary between the newer, long-
acting basal insulins, hence comparative health
economic analyses of treatments can help
healthcare payers to make decisions about how
to efficiently allocate resources to achieve
maximum healthcare gains within the con-
straints of a limited budget. In our illustrative
costs analysis, switching to degludec from other
basal insulins was estimated to achieve sub-
stantial cost savings in this cohort of patients,
despite the higher cost of degludec, due to
reductions in the frequency of severe hypo-
glycemic events and the basal insulin dose after
switching to degludec. Moreover, the estimated
average costs of an ambulance call-out and a
hospital admission due to hypoglycemia in the
greater Birmingham and surrounding area were
£242.78 and £990.96, respectively, according to
recent data at the time of this study [2, 3].
Additionally, avoiding an episode of DKA in the
UK had an estimated associated cost saving of
between £1000.00 and £1400.00 [38]. Hence,
our analysis represents a conservative estimate
of cost savings with degludec, as we excluded
direct costs associated with ambulance call-outs
and hospital admissions for hypoglycemia in
our estimation of treatment costs.
Limitations of this study include the small
sample size and the variability in baseline
HbA1c, which ranged from 5.9 to 12.2%
(41–110 mmol/mol). Another limitation was
the fact that patient recall and diaries were
relied upon as a data source for the pre-switch
6-month interval. The study also combined data
from patients on different insulin regimens and
although the most commonly used insulin was
glargine U100, there were 17 patients who had
received insulin detemir prior to switching. The
cost impact assessment was based on the glar-
gine U100 acquisition price, which, per unit, is
similar to that of insulin detemir. It is possible,
however, that baseline differences between
these insulins (e.g. dose discrepancies [39])
confound this analysis, which should therefore
be viewed as illustrative only. On the other
hand, this study shows clear benefits in terms of
both improved glycemic control and tolerabil-
ity from switching to degludec in a selected
patient group, and it helps to redress the lack of
real-world data on the effect of degludec treat-
ment in patients with recurrent, problematic
hypoglycemia or hypoglycemia unawareness.
CONCLUSIONS
The results of this real-world study indicate that
degludec may be a beneficial treatment for
patients with T1D with problematic hypo-
glycemia. In such patients, the switch to
degludec resulted in a reduced basal dose,
reduced HbA1c levels, improved QoL, and
reduced rates of DKA and hypoglycemia. Used
in appropriate targeted patients, degludec could
therefore lead to significant cost savings for the
NHS, despite its acquisition cost.
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